Overview
- Editors:
-
-
Rhoda H. Cobin
-
Division of Endocrinology, Mount Sinai Medical Center, New York, USA
-
David King Sirota
-
Division of Endocrinology, Mount Sinai Medical Center, New York, USA
Access this book
Other ways to access
Table of contents (13 chapters)
-
-
-
-
-
-
- Arthur E. Schwartz, Eugene W. Friedman
Pages 65-85
-
-
-
-
-
-
-
-
- Li-Teh Wu, Steven D. Averbuch
Pages 204-214
-
Back Matter
Pages 215-218
About this book
Thyroid carcinoma is an uncommon malignan ing the available non-human lines, as models cy. In the vast majority of patients, if treated for cell cycle studies and oncogene/anti appropriately, it is associated with a benign oncogene regulation, because they are unaware clinical course. Why then does it hold a con of the often fundamental dichotomy between tinuing fascination for so many physicians? thyroid malignancy and prognosis. Third, the The answer is probably directly dependent very nature of the benign clinical course has suggested to the major health research fund on the very benign nature of most thyroid ing agencies that thyroid cancer is not worthy maligllancies. While there are terrible excep of study in a time of scarce resources. tions, the follicular and papillary thyroid can Nothing could be further from the truth. cers behave in a way quite alien to "common" This gratifying clinical course is the very reason neoplasia, since they grow and metastasize why the study of human thyroid cancer has the slowly. We believe that if only we could under potential for contributing further to our fun stand such a transformed state, we would be able to learn a great deal about the normal and damental understanding of malignancy and, abnormal regulation of the cell cycle and im perhaps more importantly, the mechanisms by prove our understanding of cancer. which the human body can resist neoplastic However, recent advances in the biology of cells.
